Eli Lilly and Company (NYSE:LLY) Shares Up 2.9% – What’s Next?

Eli Lilly and Company (NYSE:LLY)’s share price rose 2.9% on Thursday. The company traded as high as $1,321.21 and last traded at $1,308.2070. 2,641,545 shares were traded during mid-day trading, a decline of 10% from the average daily volume of 2,943,044 shares. The stock had previously closed at $1,270.75.

More Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly broke ground on a new $5 billion manufacturing facility in Virginia, part of a more than $50 billion U.S. production expansion. The site will be Lilly’s first fully integrated facility producing both active pharmaceutical ingredients and finished medicines, including capacity for next-generation cancer treatments, and is expected to create 650 jobs. The investment should improve long-term supply capacity and reduce manufacturing bottlenecks. Lilly Richmond manufacturing facility
• Positive Sentiment: Lilly and UAE-based Mubadala Bio reportedly agreed to cooperate on packaging, logistics and advanced pharmaceutical contract manufacturing for GLP-1 medicines in Abu Dhabi. Local infrastructure could support international distribution of Mounjaro and other weight-loss products while expanding Lilly’s regional presence. Lilly Mubadala Bio GLP-1 agreement
• Neutral Sentiment: Investor attention remains elevated after Lilly recently reached a record high. Strong demand for its obesity portfolio, including Zepbound and Mounjaro, remains the central growth narrative, but the stock’s premium valuation leaves it particularly sensitive to earnings and guidance.
• Negative Sentiment: Analysts expect Lilly’s upcoming third-quarter earnings to decline, and a Zacks preview says the company lacks the typical combination of estimate revisions and earnings momentum associated with a likely beat. This raises the risk of disappointment after the stock’s strong run. Eli Lilly Q3 earnings preview
• Negative Sentiment: Lilly’s recent revenue growth has been driven primarily by higher volume rather than pricing: second-quarter sales rose 48% while medicine volume increased 60%, but average prices fell 13%. Continued price pressure could weigh on margins and make future growth increasingly dependent on prescription volume. Lilly revenue growth and pricing
• Negative Sentiment: Novo Nordisk’s CagriSema reportedly produced 25% weight loss in women, highlighting a potentially stronger competing obesity treatment and reinforcing competitive pressure on Lilly’s GLP-1 franchise.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on the company. Wells Fargo & Company upped their price objective on Eli Lilly and Company from $1,280.00 to $1,330.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Weiss Ratings raised Eli Lilly and Company from a “buy (b)” rating to a “buy (b+)” rating in a research note on Thursday, October 15th. Citigroup increased their price target on Eli Lilly and Company from $1,500.00 to $1,600.00 and gave the company a “buy” rating in a research note on Wednesday, July 15th. Cantor Fitzgerald boosted their target price on shares of Eli Lilly and Company from $1,410.00 to $1,440.00 and gave the company an “overweight” rating in a research report on Thursday, October 8th. Finally, The Goldman Sachs Group reiterated a “buy” rating and set a $1,413.00 price target on shares of Eli Lilly and Company in a research note on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, twenty-four have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $1,317.93.

Eli Lilly and Company Stock Up 2.9%

The stock has a market capitalization of $1.23 trillion, a P/E ratio of 43.90, a price-to-earnings-growth ratio of 1.71 and a beta of 0.46. The stock has a fifty day moving average price of $1,184.78 and a 200 day moving average price of $1,119.15. The company has a debt-to-equity ratio of 1.41, a current ratio of 1.35 and a quick ratio of 1.00.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings results on Wednesday, August 5th. The company reported $8.38 EPS for the quarter, topping analysts’ consensus estimates of $6.40 by $1.98. Eli Lilly and Company had a net margin of 33.53% and a return on equity of 97.83%. The business had revenue of $22.97 billion during the quarter, compared to analysts’ expectations of $20.82 billion. During the same quarter in the previous year, the company earned $6.31 EPS. The business’s quarterly revenue was up 47.7% compared to the same quarter last year. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. On average, research analysts forecast that Eli Lilly and Company will post 33.56 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, EVP Patrik Jonsson sold 6,500 shares of the company’s stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares in the company, valued at approximately $63,628,139.70. This represents a 10.72% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Donald A. Zakrowski sold 2,000 shares of Eli Lilly and Company stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $1,185.01, for a total transaction of $2,370,020.00. Following the transaction, the chief accounting officer directly owned 1,526 shares of the company’s stock, valued at approximately $1,808,325.26. This trade represents a 56.72% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 13,500 shares of company stock worth $15,958,170. 0.14% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Eli Lilly and Company

Hedge funds have recently added to or reduced their stakes in the company. Integrity Financial Corp WA grew its stake in shares of Eli Lilly and Company by 1.3% in the second quarter. Integrity Financial Corp WA now owns 639 shares of the company’s stock worth $767,000 after acquiring an additional 8 shares during the period. LCM Capital Management Inc grew its position in shares of Eli Lilly and Company by 3.3% during the third quarter. LCM Capital Management Inc now owns 253 shares of the company’s stock worth $293,000 after purchasing an additional 8 shares in the last quarter. Smith Shellnut Wilson LLC ADV boosted its stake in Eli Lilly and Company by 4.1% during the third quarter. Smith Shellnut Wilson LLC ADV now owns 203 shares of the company’s stock valued at $235,000 after buying an additional 8 shares during the last quarter. Willner & Heller LLC grew its position in Eli Lilly and Company by 1.0% in the second quarter. Willner & Heller LLC now owns 917 shares of the company’s stock worth $1,100,000 after acquiring an additional 9 shares in the last quarter. Finally, Aspiring Ventures LLC boosted its position in shares of Eli Lilly and Company by 3.7% during the second quarter. Aspiring Ventures LLC now owns 255 shares of the company’s stock valued at $306,000 after buying an additional 9 shares during the period. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company that discovers, develops, manufactures and markets medicines for a range of medical conditions. Its major therapeutic areas include diabetes and obesity, oncology, immunology, neuroscience and cardiovascular health.

The company’s portfolio includes Mounjaro and Trulicity for diabetes, Zepbound for chronic weight management, Humalog insulin, Taltz for inflammatory diseases, Verzenio for certain breast cancers and Kisunla for early symptomatic Alzheimer’s disease.